Fig. 1
From: The deubiquitinating protein OTUD6B promotes lung adenocarcinoma progression by stabilizing RIPK1
Overexpression of OTUD6B in LUAD patients predicts poor clinical prognosis. A The expression of OTUD6B in human bronchial epithelial-like cell lines (HBE) and human LUAD cell lines (SP-A-1, A549, NCL-H1395, NCL-H1975, and NCL-2087) was detected by Western blotting. B Expression of the OTUD6B protein in LUAD tissues was detected via Western blotting. N: represents adjacent nontumor tissue, T: represents LUAD tissue. C The expression of OTUD6B in LUAD tissues was detected by qPCR. D, E The expression and IHC score of OTUD6B in adjacent nontumor tissues and LUAD tissues from patients with different degrees of differentiation were detected by immunohistochemistry. F, G The expression of OTUD6B in LUAD tissues from patients with different degrees of malignancy was grouped according to TNM stage, and the levels of OTUD6B in the different groups were analyzed. H, I In the TMA-based cohort, Kaplan–Meier survival analysis was used to evaluate the clinical significance of OTUD6B expression for overall survival (OS) and recurrence-free survival (RFS). J–M Analysis of the expression level and survival prognosis of patients with clinical LUAD stratified by OTUD6B expression according to the GEO database. N The expression level and survival prognosis of LUAD patients stratified by OTUD6B expression were analyzed using the TCGA database